Biotech firm Windtree Therapeutics plans to purchase up to $700 million in BNB, the fifth-largest cryptocurrency, following its recent all-time high price of $808. The company intends to raise $520 million to facilitate these purchases, adding to an earlier commitment of $200 million in BNB. Windtree will collaborate with crypto exchange Kraken for asset custody. To finance this initiative, Windtree will secure funds through a $500 million equity line of credit and a $20 million stock-purchase agreement with another firm. Despite a recent 5% dip in its stock, Windtree shares have gained 162% over the past month. This move aligns with a broader trend among publicly traded companies, like Strategy, that are investing in various cryptocurrencies to enhance their corporate treasuries. The acquisition strategy reflects the growing interest of companies in integrating digital assets into their financial models as a means to bolster stock prices.

Source 🔗